-
Mashup Score: 2Schnitzler Syndrome: A Monoclonal Gammopathy and Autoinflammatory Condition | ASH Clinical News | American Society of Hematology - 11 month(s) ago
In 1972, the French dermatologist Liliane Schnitzler, MD, first described a rare and unusual syndrome that was eventually given her name. Schnitzler syndrome is characterized by an immunoglobulin M (IgM) monoclonal gammopathy and a unique urticarial rash, and it is often associated with additional symptoms such as bone or joint pain, enlarged lymph nodes, recurrent fever, liver or spleen…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Engineered CAR T Cells Locally Deliver Blocker of CD47 Pathway | ASH Clinical News | American Society of Hematology - 12 month(s) ago
Skip Nav Destination April 11, 2023 Ruth Jessen Hickman, MD, is a freelance medical and science writer based in Bloomington, Indiana. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated high response rates in patients…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
To combat relapse rates associated with #CAR #Tcell therapy, researchers have engineered "Orexi” CAR T cells to locally secrete CV1, a high-affinity CD47 blocker, at the tumor site, combining treatment with an orthogonally targeted #monoclonal #antibody https://t.co/FCWGIL8Wf6
-
-
Mashup Score: 0LAG3 Regulates T-Cell Activation and Inflammation in Atherosclerotic Plaques | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination March 29, 2023 Brandon May is a medical journalist based in Detroit. The immune checkpoint molecule lymphocyte activation gene-3 (LAG3) may be important for regulating T-lymphocyte activation and inflammation…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Recent research suggests that treatment with anti-LAG3 #monoclonal #antibodies may promote vascular inflammation and #atherosclerosis, a finding that could have important implications for patients with certain forms of #cancer receiving ICB therapy https://t.co/GO2OrGTmPO
-
-
Mashup Score: 0Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis - 1 year(s) ago
Anti-drug antibodies (ADA) may worsen the efficacy and safety of biologics. However, little is known about the incidence of ADAs associated with the six biologics approved for the treatment of asthma in the US.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! Incidence of Anti- #Drug #Antibodies to #Monoclonal #Antibodies in #Asthma: A #Systematic #Review and Meta- #Analysis https://t.co/HzZvHY2UmP
-
-
Mashup Score: 0
With many of the new COVID-19 vaccines not as effective against the new variants, reducing their spread without pharmaceuticals is even more critical.
Source: Infection Control TodayCategories: Infectious Disease, Latest HeadlinesTweet-
With many of the new COVID-19 variants not as effective against the new variants, reducing their spread without pharmaceuticals is even more critical. https://t.co/l4d8l1hWgU #monoclonal #vaccines #covid19 #covid19vaccines #omicron #bivalent #mrna #paxlovid
-
-
Mashup Score: 0Sutimlimab Produces Favorable Results in Patients With Cold Agglutinin Disease | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination December 5, 2022 Treatment with sutimlimab had acceptable safety and efficacy profiles in patients with cold agglutinin disease, based on the results of a study scheduled to be presented at the 64th ASH Annual Meeting…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#ASH22 Treatment with #sutimlimab, a #monoclonal #antibody that prevents CP activation, was found to have acceptable safety and efficacy profiles in patients with #ColdAgglutininDisease https://t.co/6Nn4wXQvVU
-
-
Mashup Score: 0Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies - 1 year(s) ago
Kidney transplant recipients (KTR) are at increased risk for COVID-19-associated complications. We aimed to describe the evolving epidemiology and outcome of PCR-documented SARS-CoV-2 infection in KTR followed at our institution from March 2020 to May 2022. The primary endpoint was hospitalization for COVID-19-related symptoms or death within 28Â days from diagnosis. Overall, 243 cases were…
Source: FrontiersCategories: Latest Headlines, TransplantationTweet-
Outcome of #COVID19 in #Kidney #Transplant recipients through the SARS-CoV-2 variants eras: role of #monoclonal #antibodies https://t.co/JGXRVkJ8zu. Read more in our last issue👉https://t.co/3ntSVTpQnU https://t.co/D6g9GbMStm
-
-
Mashup Score: 7Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies - 2 year(s) ago
Background and Objectives Anti–calcitonin gene-related peptide (CGRP) (receptor) antibodies are approved as preventive treatment for migraine. Recent concerns have been raised after a retrospective analysis of postmarketing case reports of elevated blood pressure (BP) associated with erenumab. In this prospective follow-up study, we aimed to assess the safety regarding BP in a real-world…
Source: NeurologyCategories: Latest Headlines, NeurologyTweet-
This study assessed whether #monoclonal anti-CGRP (receptor) antibodies increase blood pressure in patients with #migraine. Learn more: https://t.co/WMVuiNK1tF #NeuroTwitter https://t.co/lgEhpYCdYO
-
-
Mashup Score: 0Could monoclonal antibodies replace opioids for chronic pain? - 2 year(s) ago
During the pandemic, physicians used infusions of monoclonal antibodies to help patients fight off COVID-19 infections. Now, in response to the U.S. opioid crisis, researchers at UC Davis are trying to create monoclonal antibodies that can help fight chronic pain.
Source: NewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Could #monoclonal #antibodies replace opioids for #chronicpain? https://t.co/ZeyHgooFci @UCDavisMedCntr @UCDavisMed #SodiumChannels #NaV17 #NaV18 #NaV19 #pain #IASP Monthly self-injections .. down the road awhile.
-
-
Mashup Score: 0Rituximab and infliximab desensitization with anti-IgE monoclonal antibody omalizumab as adjuvant therapy: a case series - 2 year(s) ago
IgE-mediated mechanisms can be involved in HSR to biologicals. Omalizumab allows safe and successful drug administration in DD protocols previously complicated by breakthrough reactions.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! #Rituximab and #infliximab #desensitization with #anti- #IgE #monoclonal #antibody #omalizumab as #adjuvant #therapy: a case series https://t.co/V7D0KmEoBQ
-
Sharing some overlap with #dermatology, #SchnitzlerSyndrome is characterized by an #IgM #monoclonal #gammopathy and a unique urticarial rash. Learn more about this rare condition in this month's Hematologica Obscura 🩸 https://t.co/LVGhSMXOzY